There are no "issues" with using mortality as an e
Post# of 148179
Is it harder? Yes. And that's why Leronlimab will take the lead. RLFTF changed the endpoint because they weren't confident they would get stat significance.
Cytodyn is betting they will. I like people who bet on themselves.